Octanine (Human Coagulation Factor Ix)

Human Coagulation Factor IX, the active ingredient in Octanine, is a coagulation factor IX concentrate presented as a intravenous solution for intravenous use. It replaces deficient factor IX in patients with hemophilia B, helping to control and prevent bleeding episodes. GNH USA supplies Octanine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Octanine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanine is a factor IX replacement therapy used in the management of hereditary bleeding disorders that involve the intrinsic coagulation pathway.

- Hemophilia B: Provides temporary replacement of factor IX to control bleeding and support surgery. - Acquired factor IX deficiency: Restores factor IX activity to reduce bleeding risk. - Peri‑operative management: Maintains adequate factor IX levels during surgical procedures in patients with hemophilia B.

Adverse reactions to Octanine are generally related to its protein nature and the infusion process.

Common Side Effects: - Mild fever - Headache - Nausea - Transient infusion‑related chills - Localized erythema at the infusion site - Mild arthralgia

Serious or Rare Side Effects: - Anaphylactic reaction - Development of inhibitors (neutralizing antibodies) to factor IX - Thrombotic events - Severe hypersensitivity including serum sickness - Acute hemolysis - Renal impairment associated with large‑volume infusions.

Octanine should be used under the supervision of a qualified healthcare professional familiar with hemophilia management.

- Dosing individualisation: Adjust dose based on factor IX activity levels and clinical response. - Monitoring: Regularly assess factor IX activity and inhibitor development. - Infection risk: Use aseptic technique to avoid contamination of the product. - Pregnancy and lactation: Use only if clearly needed; weigh benefits against potential risks. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanine may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Antifibrinolytics (e.g., tranexamic acid) combined with high‑dose factor IX may increase thrombosis risk. - Immune‑modulating therapies that could promote inhibitor formation.

Moderate Interactions (Monitor Closely): - Concomitant use of other clotting factor concentrates. - Certain antibiotics (e.g., vancomycin) that may alter infusion tolerance. - Vaccines :      -     """"  ""  """ ""  "" "" "" "" """ "" "" """ "" "" """ "" " " " "" " " " " """ " " " " " " " " " "" " " " " " " " " " " " " " " " " " " " " " "